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Abstract 
Context: Tobacco smoke includes a mix of carcinogens implicated in the etiology of bladder 
cancer (BC) and renal cell cancer (RCC). 
Objective: We reviewed the impact of tobacco exposure on BCC and RCC incidence and 
mortality, and whether smoking cessation decreases the risk. 
Evidence acquisition: A systematic review of original articles in English was performed in 
August 2013. Meta-analysis of risks was performed using adjusted risk ratios where 
available. Publication bias was assessed using Begg and Egger tests. 
Evidence synthesis: We identified 2683 papers, of which 114 fulfilled our inclusion criteria,  
of which 90 studies investigated BC and 24 investigated RCC. The pooled relative risk (RR) 
of BC incidence was 2.57 (95% confidence interval [CI] 2.37±2.78) for all smokers, 3.37 
(3.01±3.78) for current smokers, and 1.98 (1.76±2.22) for former smokers. The 
corresponding pooled RR of BC disease-specific mortality (DSM) was 1.79 (1.40±2.29), 1.89 
(1.29±2.78) and 1.66 (1.10±2.52). The pooled RR of RCC incidence was 1.27 (1.18±135) for 
all smokers, 1.29 (1.14±1.46) for current smokers, and 1.14 (1.06±1.22) for former smokers. 
The corresponding RCC DSM risk was 1.20 (1.02±1.41), 1.32 (1.08±1.62), and 1.01 (0.85±
1.18). 
Conclusions: We present an up-to-date review of tobacco smoking and BC and RCC 
incidence and mortality. Tobacco smoking significantly increases the risk of BC and RCC 
incidence. BC incidence and DSM risk are greatest in current smokers and lowest in former 
smokers, indicating that smoking cessation confers benefit. We found that secondhand smoke 
exposure is associated with a significant increase in BC risk. 
Patient summary: Tobacco smoking affects the development and progression of bladder 
cancer and renal cell cancer. Smoking cessation reduces the risks of developing and dying 
from these common cancers. We quantify these risks using the most up-to-date results 
published in the literature. 
 
 
1. Introduction 
*Manuscript
Tobacco smoke is the commonest human carcinogen. The World Health Organization 
estimates that in 2013 there were more than one billion smokers worldwide [1] and 
approximately six million people die each year from tobacco-related illnesses. These deaths 
include an estimated one million nonsmokers who obtained exposure indirectly from 
environmental tobacco smoke or secondhand smoking (SHS) [1]. The majority of smoking-
related deaths occur because of cardiovascular and pulmonary diseases or malignancies. The 
risk of tobacco-related illnesses varies with the duration and intensity of smoking [2], the 
type of tobacco and mode of administrationDQGDQLQGLYLGXDO¶VDELOLW\WRGHWR[LI\
carcinogens. Tobacco can be consumed in a variety of forms such as smoking cigarettes, 
cigars, pipes, and shisha (a molasses-tobacco hybrid compound), chewing, and inhalation as 
snuff, and can be used in isolation or in combination with illicit drugs such as opium and 
marijuana [3]. Tobacco can be prepared via flue (blonde) or air curing (black). The latter is 
considered to be more carcinogenic to the urinary tract owing to its higher concentration of 
nitrosamines, biphenyls, and arylamines [2,4,5]. With regard to carcinogen detoxification, 
variations in the activity of N-acetyl-transferase 2 (NAT2) and glutathione S-transferase mu 
P1 (GSTM1) because of polymorphisms appear to affect cancer risk from smoking [6]. It is 
also evident that tobacco smoke can induce changes in the DNA damage response machinery, 
which can additively or synergistically impair the host response to carcinogens [7,8]. 
Bladder cancer (BC) and renal cell cancer (RCC) are among the commonest smoking-related 
human malignancies. In 2013 there were an estimated 382 700 new cases of BC and 338 000 
of RCC worldwide, with 143 000 and 150 300 resultant deaths, respectively [9,10]. Both 
tumors are more common in males than females, reflecting the role of tobacco smoking, 
occupational carcinogen exposure, and lifestyle in their etiology. Tobacco smoke inhalation 
appears to be the commonest risk factor for BC, accounting for approximately 50% of BC 
cases [6] and 20±25% of RCC cases [11]. Further risk factors for RCC include obesity and 
hypertension. For both cancers, risk may be modified by genetic predisposition and 
interaction with further carcinogens [12], and altering smoking exposure may change the 
natural history of the disease. For example, smoking cessation may reduce BC recurrence 
rates [13], although conflicting data exist [14,15]. Regardless of this contradiction, smoking-
induced DNA damage (as detected in either blood or urine) reduces to normal levels after 
cessation [16]. 
Here we present a systematic review of the literature and meta-analysis of the associations 
between smoking and both BC and RCC. We analyze both incidence and mortality, and 
specifically combine risks for SHS and non±smoking-related tobacco exposures. Owing to 
the causal relationship between active smoking and BC, there has been strong reason to 
suspect that SHS (also known as environmental tobacco smoke or passive smoking) has a 
role in carcinogenesis. The strength of this association has been emphasized by evidence that 
urinary levels of carcinogens are greater in subjects exposed to SHS than those not subjected 
to this exposure [16]. 
 
2. Evidence acquisition 
2.1. Systematic review 
We searched PubMed in August 2013 for all original articles in English using the string terms 
³tobacco´, ³smoking´ AND ³bladder cancer´, and ³tobacco´, ³smoking´ AND ³kidney 
cancer´. Articles were included in the meta-analysis if they met the following inclusion 
criteria: (i) case-control, cohort, or nested case-control studies published as original articles in 
English investigating the relationship between smoking and the risk of BC or RCC in 
humans; (ii) incidence or disease-specific mortality (DSM) as outcome; and (iii) odds ratio 
(OR), hazard ratio (HR), or relative risk (RR) estimates with 95% confidence intervals (CIs), 
or enough information to calculate them, reported. We excluded summary data (reviews) and 
reports not focusing on our research question or describing molecular effects in cell lines. In 
cases of multiple reports from the same series, we used the most recent one. Previous meta-
analyses and systematic reviews were only included for discussion purposes when describing 
potential carcinogenic processes. We report our findings in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [17]. 
 
2.2. Data abstraction 
From each study included in the meta-DQDO\VLVZHH[WUDFWHGWKHILUVWDXWKRU¶Vlast name, 
publication year, country, study period, gender of study participants, cancer type (BC or 
RCC), number of cases and controls (for case-control or nested studies) or number of events 
and cohort size (for cohort studies), smoking status (all, former, or current), tobacco products 
(cigarettes, cigars, or pipes), SHS exposure, adjustment variables, and RRs or ORs with 95% 
CIs for each smoking status or tobacco product. If multiple RRs or ORs were presented in the 
original articles, we extracted the estimates from the maximally adjusted model to reduce the 
risk of possible unmeasured confounding [18]. 
 
2.3. Statistical methods 
Because cancer is a relatively rare outcome, we assumed that ORs, risk ratios, and rate ratios 
were all comparable estimates of the RR. To conduct the meta-analysis, measures of 
association and the corresponding CIs were translated into log(RR) values and their variances 
[18]. 
BC and RCC incidence and DSM risks were computed separately. We used the maximum 
adjusted risk estimates when reported. We computed pooled RRs for BC and RCC incidence 
and DSM risks using a random effects model to take into account the heterogeneity between 
risk estimates [19]. We evaluated potential heterogeneity among studies using the Cochran Q 
statistic and I2, that is, the proportion of total variation contributed by between-study variance 
[20]. 
To investigate potential sources of heterogeneity, we carried out stratified analyses according 
to study area (Europe, America, Asia, and Oceania), study design (case-control and cohort 
studies), and gender. We also tested whether the corresponding stratified pooled RR 
estimates differed significantly across the strata considered. 
Potential publication bias was evaluated by visual inspection of funnel plots, Egger linear 
regression [21], and the Begg rank correlation test [22]. 
Stata statistical software (version 12.0, StataCorp LP, College Station, TX, USA) was used 
for statistical analysis. 
 
3. Evidence synthesis 
Our search identified 2683 reports (1237 BC, 225 RCC, 8 both, and 1213 unrelated cancers). 
All abstracts were read in full by one author (M.G.C.) before selection of 248 papers for 
extraction. From these full reports, we identified 114 articles (Supplementary Appendix 1) 
fulfilling our inclusion criteria for the meta-analysis (Supplementary Fig. 1). Outcomes for 
51 404 BC cases and 64 602 controls, and for 16 007 RCC cases and 18 876 controls were 
included in the meta-analysis. Specifically, 109 papers included data on disease incidence or 
mortality in relation to cigarette smoking, eight papers concentrated on alternative means of 
tobacco exposure (eg, chewing), and five evaluated SHS (passive smoking). The majority of 
the reports focused on BC (79%). 
 
3.1. BC incidence 
We stratified BC risk according to current, former (no longer smoking at the time of 
interview), all (data for both current and former smokers, as well as data reported for ever 
smokers), and never smoker history (Table 1). There were significant pooled RRs for BC 
incidence among all smokers of cigarettes (RR 2.57, 95% CI 2.37±2.78; I2 = 87.7%, p < 
0.001), current smokers (RR 3.37, 95% CI 3.01±3.78; I2 = 82.2%, p < 0.001), and former 
smokers (RR 1.98, 95% CI 1.76±2.22; I2 = 78.6%, p < 0.001) when compared to never 
smokers. Current smokers had the greatest risk (Fig. 1). When stratified by study design, a 
stronger association between smoking and BC risk was observed in case-control studies than 
in cohort studies (Table 1). Publication bias for BC among all smokers was assessed using 
Begg (p = 0.03) and Egger (p = 0.13) tests. Visual inspection of a funnel plot could not rule 
out publication bias (Supplementary Fig. 2). We further stratified the data by gender and 
geographic region. Although males (RR 2.55, 95% CI 2.18±2.98; I2 = 91.6%, p < 0.001) had 
a slightly higher risk than females (RR 2.19, 95% CI 1.80±2.65; I2 = 83.3%, p < 0.001), 
pooled RR estimates did not differ across gender (p = 0.2). The majority of data came from 
studies based in North America (listed as Americas) and Europe. The highest pooled RR was 
observed in studies carried out in Europe (RR 2.98, 95% CI 2.67±3.36; I2 = 86.2%, p < 0.001; 
Table 3), although we did not see a difference across geographic region (p = 0.08). Among 
groups that used non-cigarette tobacco, cigar smoking (RR 1.62, 95% CI 1.18±2.22; I2 = 
39.4%, p = 0.2) and pipe smoking (RR 1.49, 95% CI 1.18±1.88; I2 = 0.0%, p = 0.6) were both 
associated with significantly higher BC risk (Supplementary Table 2), although pooled RRs 
estimates were based on just a few studies. We did not observe a significant difference in 
pooled RR for smoking between non-cigarette tobacco products and cigarettes (p = 0.1). 
 
3.2. BC mortality 
BC mortality is less extensively reported in the literature. All smokers (RR 1.79, 95% CI 
1.40±2.29; I2 = 93.3%, p < 0.001), current smokers (RR 1.89, 95% CI 1.29±2.78; I2 = 90.3%, 
p < 0.001) and former smokers (RR 1.66, 95% CI 1.10±2.52; I2 = 95.9%, p < 0.001) had a 
higher risk of BC mortality compared to never smokers (Table 1). Cigar smoking had a 
nonsignificant higher mortality risk (data not shown). For current and former smokers, the 
Begg (p = 1.0 and 0.4) and Egger (p = 0.3 and 0.3) tests for publication bias confirmed that 
there was no significant publication bias. There were no significant differences by gender (p 
= 0.9) or geographic region (p = 0.4; Table 3). 
 
3.3. RCC incidence 
The risk of developing RCC was significantly higher for all smokers (RR 1.27, 95% CI 1.18±
1.35; I2 = 57.9%, p < 0.001), current smokers (RR 1.29, 95% CI 1.14±1.46; I2 = 74.4%, p < 
0.001), and former smokers (RR 1.14, 95% CI 1.06±1.22; I2 = 14.5%, p = 0.3; Table 2) 
compared to nonsmokers. Current smokers had the greatest risk (Fig. 2). Begg and Egger 
tests for publication bias for all smokers (both p = 0.5), current smokers (p = 0.2 and 0.7, 
Supplementary Fig. 3), and former smokers (p = 0.9 and 0.3) showed that there was no 
significant publication bias. A significant difference (p = 0.02) in pooled RRs emerged when 
we stratified by study geographic region; the greatest pooled RR for RCC was observed for 
Oceania (RR 1.74, 95% CI 1.14±2.66; I2 = 70.2%, p = 0.07) and the lowest for Europe (RR 
1.02, 95% CI 0.91±1.12; I2 = 0.0%, p = 0.6). Stratification by gender revealed that males (RR 
1.42, 95% CI 1.25±1.62; I2 =55.0%, p = 0.001) had a slightly higher pooled RR for RCC than 
females (RR 1.32, 95% CI 1.16±1.51; I2 = 26.6%, p = 0.14), although the difference was not 
significant (p = 0.4). There were insufficient data on non-cigarette tobacco use and RCC risk. 
 
3.4. RCC mortality 
The risk of death from RCC among tobacco users was elevated for all smokers (RR 1.20, 
95% CI 1.02±1.41; I2 =51.6%, p = 0.044), current smokers (RR 1.32, 95% CI 1.08±1.62; I2 
=25.8%, p = 0.3), and former smokers (RR 1.01, 95% CI 0.85±1.18; I2 = 14.5%, p = 0.3; 
Table 2). Stratification by geographic region revealed that the greatest RR for RCC was in 
the Americas, but the pooled RR did not differ (p = 0.8), although the numbers are small 
(Table 3). 
 
3.5. Secondhand smoking 
The pooled RR of BC from secondhand smoking was 1.44 (95% CI 1.05±2.0; I2 = 59.8%, p = 
0.021) and of RCC was 1.43 (95% CI 0.89±2.28; I2 = 55.3%, p = 0.08; data not shown). 
There were no data on DSM risk for SHS in this data set for either cancer type. 
 
3.6. Discussion 
3.6.1. Tobacco products and bladder carcinogenesis 
We found that tobacco consumption increases the risk of BC incidence and DSM, and we 
provide up-to-date and more precise quantitative estimates than previously available [6]. 
Although certain occupations (such dye workers) may have high individual risk elevations 
for BC, tobacco smoking appears to be responsible for most BC cases because of its high 
prevalence [23]. 
Tobacco is a rich source of polycyclic aromatic hydrocarbons, aromatic amines, and N-
nitroso compounds, which cause DNA damage via bulky adduct formation, single- and 
double-strand DNA breaks, and base modifications [24]. These acquired events complement 
DQLQGLYLGXDO¶Vgenetic predisposition to smoking-related cancer. For example, first-degree 
relatives of BC patients have a 50±100% higher risk, which increases if the relative was 
diagnosed at <60 yr of age [25] and in a dose-dependent manner [26]. 
Tobacco carcinogens are mostly metabolized by xenobiotic enzymes such as N-
acetyltransferases (NATs) and glutathione S-transferases. These enzymes have alleles with 
different activity profiles. For example, individuals with slow NAT2 acetylation exhibit less 
efficient detoxification of carcinogens, leading to higher accumulation in urothelium. There is 
general consensus that individuals with slow NAT2 acetylation have a higher BC risk (up to 
50%) and that this higher risk is mostly seen in smokers. Approximately 50% of individuals 
of European, 35% of African, and 15% of Asian descent may have slow acetlyation [23]. 
Genome-wide association studies have recently focused on interactions between smoking and 
single nucleotide polymorphisms in BC patients, but a conclusive link has not been shown to 
date [27]. 
 
3.6.2. Tobacco products and renal carcinogenesis 
We found that RCC was 1.3-fold more common among smokers, in agreement with previous 
data [28]. In addition, the RCC DSM risk was 1.3-fold higher among current smokers. The 
triad of obesity, hypertension, and smoking are accepted as the main contributors to RCC 
[29±31]. It is thought that obesity confers risk through an increase in lipid peroxidation by-
products that can cause DNA adducts [32]. It has also been shown that obese patients have 
higher circulating levels of insulin-like growth factor-1 (IGF-1) and vascular endothelial 
growth factor (VEGF), which have roles in cell proliferation. Patients with hypertension also 
have higher levels of lipid peroxidation by-products, and it is thought that hypertension 
results in renal tubular damage, making the kidney more susceptible to circulating 
carcinogens [30,32]. It is thought that tobacco smoking adds to this and itself promotes the 
formation of oxygen free radicals that can cause DNA damage. Tobacco smoking leads to 
more aggressive RCC phenotypes, and patients who smoke at the time of nephrectomy have a 
lower survival rate [33,34]. There is no universal consensus on whether this is due to direct 
effects of tobacco or the characteristics of smokers, who are perhaps less likely to seek health 
care and may suffer from delayed presentation. 
A number of genes increase susceptibility to RCC, including von Hippel-Lindau (VHL) [32]. 
There are limited data on gene-environment interactions; however, in the last decade a link 
has been made between obesity and VHL tumor suppressor inactivation through mutations 
caused by reactive oxygen species [32]. Little is known about smoking and these interactions. 
 
3.6.3. Patient outcomes 
Smoking reduces perioperative performance status and impairs wound healing. 
Consequently, the risk of perioperative complications, disease progression, and tumor 
recurrence after treatment is higher [35], as is the incidence of second smoking-related 
cancers after successful treatment [36], among smokers when compared to nonsmokers. 
Disease-related patterns may differ between the malignancies. For RCC, smoking is 
associated with higher stage at diagnosis [35]. For BC, post-treatment recurrence risks were 
elevated in the majority of studies, although the hazard ratio (HR) varied in this review from 
1.57 to 3.67 (data not shown) [13,37]. Despite these outcomes, fewer than 50% of patients 
stop smoking after their cancer diagnosis [38]. 
 
3.6.4. Secondhand smoking 
One of the main methodologic limitations in measuring the effects of smoking on health 
outcomes is the difficulty in controlling for and measuring SHS exposure. In the articles 
included in our meta-analysis, researchers used household exposure, workplace exposure, or 
any environmental exposure methods to quantify SHS. However, these lack precision and 
make the strength of conclusions weaker than those for smokers. 
 
3.6.5. Limitations 
There are various limitations to our study. In terms of search strategy and data collection, we 
chose to review only studies we found via the Medline database through PubMed, which may 
have limited the number of studies included. Furthermore, we only looked at studies written 
in English. However, a study by Moher et al [39] provides no evidence that language-
restricted meta-analyses lead to biased estimates of intervention effectiveness. 
In addition, there are concerns about the reliability and validity of smoking status 
questionnaires and interviews (smokers can under-report consumption or suffer recall bias). 
Most series were retrospective case-control studies, which may suffer from inaccurate 
documentation of smoking history. Prospective studies have fewer potential sources of bias, 
but under-reporting of smoking affects these studies too. Sweeney and Farrow [40] make the 
interesting point that smokers, who have poorer outcomes, may be under-represented because 
they deteriorate at an earlier stage compared to nonsmokers, and hence may not be available 
for studies. It is also accepted that SHS is hard to measure, and contamination is likely to 
confound risk estimates for nonsmokers [41]. It can be difficult to combine tobacco-smoking 
studies that may have looked at different tobacco-smoking combinations and used different 
definitions of smoking status. Hence, we chose not to analyze dose-response data (intensity 
of smoking) and instead used summary categories. Another potential pitfall of meta-analyses 
is the failure to appreciate the role of potentially confounding variables. To counter this, we 
used maximally adjusted risk estimates where provided. While we were not able to stratify 
for all characteristics (eg, ethnicity), we do report risk estimate differences by gender and 
geographic region. It would have been interesting to know whether the effect of tobacco 
smoking on BC incidence and DSM is similar in non±muscle-invasive (NMIBC) and muscle-
invasive bladder cancer (MIBC), but studies included in this meta-analysis did not report 
results according to cancer stage. In 1987, Jensen et al found no difference in the effect of 
smoking on incidence between NMIBC and MIBC [15]. 
Finally, during data analysis, Begg and Egger tests provided p values that were not 
significant for publication bias, even though visual inspection of funnel plots could not 
completely rule our this possibility. 
 
4. Conclusions 
We provide the largest meta-analysis to date on the relationship between tobacco smoking 
and BC and RCC incidence and mortality. Smoking involves a higher risk of cancer 
incidence and DSM, consistent with the literature. For BC, the incidence and DSM risk are 
greatest in current smokers and lowest in former smokers, indicating that cessation confers 
benefit. In 1988 smoking was responsible for 30±40% of BC and RCC cases [42]. Since then, 
some authors have suggested there has been an overall modest decrease in incidence and 
mainly mortality, particularly for BC [43±45]. Obesity is an increasing health problem and is 
probably partly responsible for the plateau in RCC incidence [42,45]. Despite reductions in 
occupational exposures and smoking bans, smoking patterns in some countries remain high 
and the need to promote smoking cessation continues. 
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Fig. 1 ± Forest plot of study-specific and pooled relative risk (RR) with 95% confidence 
interval (CI) for the incidence of bladder cancer among current cigarette smokers 
compared to nonsmokers. The studies are listed in Supplementary Appendix 1. 
 
Fig. 2 ± Forest plot of study-specific and pooled relative risk (RR) with 95% confidence 
interval (CI) for the incidence of renal cell cancer among current cigarette smokers 
compared to nonsmokers. The studies are listed in Supplementary Appendix 1. 
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Illustration
Table 1 ± Pooled relative risk (PRR) and 95% confidence interval (CI) for bladder 
cancer incidence and mortality by selected cigarette smoking status compared to 
nonsmokers 
 Incidence Mortality 
 n a PRR (95% CI) I2, % (p value b) n a PRR (95% CI) I2, % (p value b) 
All smokers       
 Case-control studies 119 2.73 (2.50±2.99) 89.4 (<0.001) ± ± ± 
 Cohort studies 33 2.06 (1.80±2.35) 68.3 (<0.001) 19 1.79 (1.40±2.29) <0.001 
 Overall 152 2.57 (2.37±2.78) 87.7 (<0.001) 19 1.79 (1.40±2.29) 93.3 (<0.001) 
Ever smokers 
 Case-control studies 48 2.62 (2.28±3.03) 89.1 (<0.001) 0 ± ± 
 Cohort studies 7 1.52 (1.25±1.83) 0.0 (0.7) 2 1.84 (0.74±4.59) 94.3 (<0.001) 
 Overall 55 2.46 (2.16±2.81) 87.9 (<0.001) 2 1.84 (0.74±4.59) 93.1 (<0.001) 
Current smokers 
 Case-control studies 37 3.68 (3.24±4.18) 82.0 (<0.001) 0 ± ± 
 Cohort studies 11 2.53 (2.07±3.09) 69.8 (<0.001) 9 1.89 (1.29±2.78) 90.3 (<0.001) 
 Overall 48 3.37 (3.01±3.78) 82.2 (<0.001) 9 1.89 (1.29±2.78) 90.3 (<0.001) 
Former smokers 
 Case-control studies 34 2.00 (1.73±2.31) 82.2 (<0.001) 0 ± ± 
 Cohort studies 15 1.94 (1.59±2.36) 63.3 (<0.001) 8 1.66 (1.10±2.52) 95.9 (<0.001) 
 Overall 49 1.98 (1.76±2.22) 78.6 (<0.001) 8 1.66 (1.10±2.52) 95.9 (<0.001) 
a
 Number of comparisons. Some studies include separate estimates for males and females and 
for smoking category. 
b
 p value for heterogeneity. 
 
 
 
Table 2 ± Pooled relative risk (PRR) and 95% confidence interval (CI) for renal cell 
cancer incidence and mortality by selected cigarette smoking status compared to 
nonsmokers 
 Incidence Mortality 
 n a PRR (95% CI) I2, % (p value b) n a PRR (95% CI) I2, % (p value b) 
All smokers 
 Case-control studies 52 1.25 (1.15±1.36) 64.0 (<0.001) ± ± ± 
 Cohort studies 18 1.31 (1.19±1.44) 18.1 (0.2) 8 1.20 (1.02±1.41) 51.6 (<0.044) 
 Overall 70 1.27 (1.18±1.35) 57.9 (<0.001) 8 1.20 (1.02±1.41) 51.6 (<0.044) 
Ever smokers 
 Case-control studies 14 1.45 (1.27±1.66) 45.4 (0.034) 0 ± ± 
 Cohort studies 0 ± ± 1 ± ± 
 Overall 14 1.45 (1.27±1.66) 45.4 (0.034) 1 1.30 (0.92±1.84) ± 
Current smokers 
 Case-control studies 20 1.27 (1.08±1.49) 78.5 (<0.001) 0 ± ± 
 Cohort studies 8 1.33 (1.01±1.63) 57.2 (<0.023) 4 1.32 (1.08±1.62) 25.8 (0.3) 
 Overall 28 1.29 (1.14±1.46) 74.4 (<0.001) 4 1.32 (1.08±1.62) 25.8 (0.3) 
Former smokers 
 Case-control studies 18 1.09 (0.997±1.19) 26.5 (0.2) 0 ± ± 
 Cohort studies 10 1.26 (1.12±1.43) 0.0 (0.9) 3 1.01 (0.85±1.18) 14.5 (0.3) 
 Overall 28 1.14 (1.06±1.22) 14.5 (0.3) 3 1.01 (0.85±1.18) 14.5 (0.3) 
a
 Number of comparisons. Some studies include separate estimates for males and females and 
for smoking category. 
b
 p value for heterogeneity. 
 
 
Table
Table 3 ± Pooled relative risk (PRR) and 95% confidence interval (CI) for bladder and 
renal cell cancer incidence and mortality for ever cigarette smokers compared to 
nonsmokers stratified by gender and geographic region 
 Incidence Mortality 
 n a PRR (95% CI) I2, % (p value b) n a PRR (95% CI) I2, % (p value b) 
Bladder cancer 
Gender c 
 Male 43 2.55 (2.18±2.98) 91.6 (<0.001) 7 2.45 (1.61±3.14) 90.7 (<0.001) 
 Female 33 2.19 (1.80±2.65) 83.3 (<0.001) 3 2.49 (1.45±4.27) 87.3 (<0.001) 
 Mixed 76 2.74 (2.47±3.04) 85.9 (<0.001) 8 1.35 (1.00±1.80) 86.4 (<0.001) 
Study area 
 Europe 66 2.98 (2.67±3.36) 86.2 (<0.001) 6 2.26 (1.87±2.72) 37.6 (0.2) 
 Asia 16 2.26 (1.79±2.86) 83.3 (<0.001) 5 1.56 (1.24±1.97) 0.0 (0.8) 
 Americas 62 2.36 (2.10±2.65) 88.6 (<0.001) 8 1.77 (1.10±2.82) 97.2 (<0.001) 
 Africa 8 2.01 (1.25±3.21) 88.5 (<0.001) 0 ± ± 
Renal cell cancer 
Gender c 
 Male 21 1.42 (1.25±1.62) 55.0 (0.001) 3 1.12 (0.85±1.47) 0.0 (0.6) 
 Female 19 1.32 (1.16±1.51) 26.6 (<0.14) ± ± ± 
 Mixed 30 1.16 (1.06±1.27) 65.0 (<0.001) 4 1.23 (0.99±1.53) 70.3 (0.009) 
Study area 
 Europe 16 1.02 (0.91±1.12) 0.0 (0.6) 1 1.30 (0.92±1.84) ± 
 Asia 5 1.19 (1.01±1.41) 27.9 (0.2) 3 1.12 (0.85±1.47) 0.0 (0.6) 
 Americas 46 1.30 (1.20±1.40) 61.9 (<0.001) 4 1.22 (0.95±1.58) 76.8 (0.005) 
 Oceania 2 1.74 (1.14±2.66) 70.2 (0.07) 0 ± ± 
a
 Number of comparisons. Some studies include separate estimates for males and females 
and/or smoking category. 
b
 p value for heterogeneity. 
c
 The sum does not add up to the total number of studies in the meta±analysis since only 
studies reporting estimates separately for men and women were selected. 
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Supplementary Figure 1 Flowchart of selection of studies for inclusion in the meta-
analysis. 
Supplementary Figure 2 Funnel plot for incidence of Bladder Cancer in relation to all 
cigarette smoking with respect to nonsmoking. 
Supplementary Figure 3 Funnel plot for incidence of Renal Cell Cancer in relation to all 
cigarette smoking with respect to nonsmoking. 
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Supplementary table 1a All study data for Bladder Cancer Incidence 
 
Author Year  
Years of 
follow up Journal Region 
Study 
Design Risk group Cases Controls Gender 
Risk 
effect 
Lower 
CI 
Upper 
CI 
Ahmad MR, 
2010 2010 2009 
J Ayub Med 
Coll 
Abbottabad. Asia 
Case 
Control 
Ever 
smoker 50 100 Mixed 
   
 
19.5   4.7   81.3  
Ahmad MR, 
2012 2012 1987-2005 JPMA Asia 
Case 
Control 
Ever 
smoker 50 99 Mixed  13.1   4.2   40.9  
Akiba S et al, 
1990 1990 1966-1981 
Environmental 
Health 
Perspectives Asia Cohort 
Ever 
smoker 120 0 Males  1.7   1.1   2.7  
Akiba S et al, 
1990 1990 1966-1981 
Environmental 
Health 
Perspectives Asia Cohort 
Ever 
smoker 13 0 Females  1.9   1.0   3.4  
Alberg AJ, 
2007 2007 
1963 and 
1975 Am J Epi Americas Cohort Ex smoker 11 0 Mixed  1.2   0.50   2.5  
Alberg AJ, 
2007 2007 
1963 and 
1975 Am J Epi Americas Cohort Ex smoker 57 0 Mixed  2.3   1.5   3.4  
Alberg AJ, 
2007 2007 
1963 and 
1975 Am J Epi Americas Cohort 
Current 
smoker 67 0 Mixed  2.6   1.7   3.9  
Alberg AJ, 
2007 2007 
1963 and 
1975 Am J Epi Americas Cohort 
Current 
smoker 48 0 Mixed  2.7   1.6   4.7  
Augustine A, 
1988 1988 1969-1984 Cancer res Americas 
Case 
Control 
Ever 
smoker 65 205 Females  0.62   0.42  0.91 
Augustine A, 
1988 1988 1969-1984 Cancer res Americas 
Case 
Control 
Ever 
smoker 390 1121 Males  0.70   0.58  0.84 
Baena AV, 
2006 2006 1989-1995 
Eur J Cancer 
Prev Europe 
Case 
Control 
Ever 
smoker 73 63 Males  53.7   4.6   628.0  
Baris D, 2009 2009 2001-2004 
J Natl Cancer 
Inst Americas 
Case 
Control Ex smoker 602 698 Mixed  2.3   1.9   2.8  
Baris D, 2009 2009 2001-2004 
J Natl Cancer 
Inst Americas 
Case 
Control 
Current 
smoker 374 204 Mixed  5.2   4.0   6.6  
Bedwani R, 1997 1994-1996 Int J cancer Africa Case Ex smoker 28 22 Males  4.4   1.7   11.3  
Table
1997 Control 
Bedwani R, 
1997 1997 1994-1996 Int J cancer Africa 
Case 
Control 
Current 
smoker 109 79 Males  6.6   3.1   13.9  
Bjerregaard 
BK, 2006 2006 1991-2004 Int J Cancer Europe Cohort Ex smoker 184 0 Mixed  2.3   1.7   2.9  
Bjerregaard 
BK, 2006 2006 1991-2004 Int J Cancer Europe Cohort 
Current 
smoker 234 0 Mixed  4.0   3.1   5.1  
Bjerregaard 
BK, 2006 2006 1992-2004 
Cancer 
causes 
Control Europe Cohort Ex smoker 62 0 Mixed  5.5   3.1   9.9  
Bostrom PJ, 
2012 2012 1986-2008 BJU Int Americas Cohort 
Current 
smoker 174 0 Mixed  1.6   1.1   2.3  
Brennan P, 
2001 2001 1976-1996 CCC Europe 
Case 
Control Ex smoker 101 314 Females  0.67   0.48  0.93 
Brooks DR, 
1992 1992 1984-88 Am J Ind Med Americas Cohort 
Ever 
smoker 372 0 Mixed  1.5   1.1   1.9  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control Ex smoker 36 40 Females  1.2   0.69   2.1  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control Ex smoker 287 305 Males  1.7   1.2   2.4  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control 
Ever 
smoker 118 85 Females  1.9   1.2   2.9  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control 
Ever 
smoker 566 490 Males  2.1   1.5   2.9  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control 
Current 
smoker 82 45 Females  2.6   1.6   4.3  
Burch JD, 
1989 1989 1979-1982 Int J Cancer Americas 
Case 
Control 
Current 
smoker 279 185 Males  2.7   1.8   3.9  
Burns PB, 
1991 1991 1980 CCC Americas 
Case 
Control 
Ever 
smoker 1176 1112 Males  2.3   1.9   2.7  
Burns PB, 
1991 1991 1980 CCC Americas 
Case 
Control 
Ever 
smoker 313 656 Females  2.4   1.9   2.7  
Burns PB, 
1991 1991 1980 CCC Americas 
Case 
Control 
Ever 
smoker 132 237 Males  3.0   1.9   4.8  
Burns PB, 
1991 1991 1980 CCC Americas 
Case 
Control 
Ever 
smoker 56 146 Females  3.8   2.2   6.4  
Cao W, 2005 2005 1994-1997 Cancer Americas 
Case 
Control 
Ever 
smoker 191 92 Mixed  3.1   1.7   5.9  
Cartwright RA, 
1983 1983 1978-1981 
J Epidemiol 
Community 
Health Europe 
Case 
Control 
Ever 
smoker 150 211 Females  1.2   0.92   1.6  
Cartwright RA, 
1983 1983 1978-1981 
J Epidemiol 
Community 
Health Europe 
Case 
Control 
Ever 
smoker 840 1245 Males  1.6   1.2   2.0  
Castelao JE, 
2001 2001 1987-1996 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 1240 972 Mixed  2.5   2.1   3.0  
Castelao JE, 
2001 2001 1987-1996 
J Natl Cancer 
Inst Americas 
Case 
Control 
Current 
smoker 693 362 Mixed  3.8   3.1   4.7  
Chiu BC, 2001 2001 1986-1989 
Ann 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 950 1068 Males  2.5   2.0   3.1  
Chiu BC, 2001 2001 1986-1989 
Ann 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 168 259 Females  2.7   2.0   3.6  
Chiu BC, 2001 2001 1986-1989 
Ann 
Epidemiol Americas 
Case 
Control 
Current 
smoker 139 435 Males  3.7   2.8   4.9  
Chiu BC, 2001 2001 1986-1989 
Ann 
Epidemiol Americas 
Case 
Control 
Current 
smoker 149 574 Females  3.7   2.6   5.3  
Chyou PH, 
1993 1993 1965-1968 
Ann 
Epidemiol Americas Cohort Ex smoker 19 2070 Males  1.4   0.70   2.6  
Chyou PH, 
1993 1993 1965-1968 
Ann 
Epidemiol Americas Cohort 
Current 
smoker 60 3435 Males  2.9   1.7   4.9  
Claude J, 1986 1986 1977-1982 
Am J 
Epidemiol Europe 
Case 
Control 
Ever 
smoker 287 238 Males  2.3   1.6   3.3  
Claude J, 1986 1986 1977-1982 
Am J 
Epidemiol Europe 
Case 
Control 
Ever 
smoker 32 15 Females  2.9   1.4   6.0  
Clavel J et al, 
1989 1989 1984-1987 Int J Cancer Europe 
Case 
Control Ex smoker 179 182 Males  3.0   1.9   4.6  
Clavel J et al, 
1989 1989 1984-1987 Int J Cancer Europe 
Case 
Control 
Current 
smoker 259 171 Males  5.1   3.3   8.0  
Cote ML, 2012 2012 2004-2008 Cancer Americas Case Ex smoker 304 276 Mixed  0.99   0.78   1.3  
Epidemiol 
Biomarkers 
prev 
Control 
Cote ML, 2012 2012 2004-2008 
Cancer 
Epidemiol 
Biomarkers 
prev Americas 
Case 
Control 
Current 
smoker 209 124 Mixed  1.5   1.1   2.0  
D'Avanzo B, 
1995 1995 1985-1993 
Ann 
Epidemiol Europe 
Case 
Control Ex smoker 176 179 Mixed  2.2   1.5   3.3  
D'Avanzo B, 
1995 1995 1985-1993 
Ann 
Epidemiol Europe 
Case 
Control 
Current 
smoker 165 118 Mixed  3.3   2.2   5.0  
De Stefani E, 
1991 1991 1987-1989 Cancer Americas 
Case 
Control Ex smoker 36 79 Males  5.9   1.7   20.7  
De Stefani E, 
1991 1991 1987-1989 Cancer Americas 
Case 
Control 
Current 
smoker 52 64 Females  11.9   3.3   42.2  
Demirel F, 
2008 2008 2001-2006 
Int Urol 
Nephrol Europe 
Case 
Control Ex smoker 56 76 Mixed  4.1   2.4   7.0  
Demirel F, 
2008 2008 2001-2006 
Int Urol 
Nephrol Europe 
Case 
Control 
Current 
smoker 80 92 Mixed  4.8   2.9   8.0  
Donato F, 
1997 1997 1990-1992 
Eur J 
Epidemiol Europe 
Case 
Control Ex smoker 3 12 Females  2.4   0.40   14.7  
Donato F, 
1997 1997 1990-1992 
Eur J 
Epidemiol Europe 
Case 
Control Ex smoker 61 161 Males  4.8   2.2   10.7  
Donato F, 
1997 1997 1990-1992 
Eur J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 66 114 Males  8.4   3.7   19.0  
Donato F, 
1997 1997 1990-1992 
Eur J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 15 36 Females  12.0   3.3   44.1  
Engeland A, 
1996 1996 1964-1965 CCC Europe Cohort Ex smoker 6 0 Females  1.5   0.60   3.5  
Engeland A, 
1996 1996 1964-1965 CCC Europe Cohort Ex smoker 62 0 Males  2.1   1.3   3.2  
Fortuny J, 
1999 1999 1975-1995 Int J Cancer Europe 
Case 
Control Ex smoker 41 267 Mixed  1.4   0.79   2.5  
Fortuny J, 
1999 1999 1975-1995 Int J Cancer Europe 
Case 
Control 
Current 
smoker 65 185 Mixed  3.6   2.1   6.3  
Grant EJ, 2012 2012 1963-1991 Radiat Res Asia Cohort Ex smoker 45 0 Mixed  1.2   0.83   1.8  
Grant EJ, 2012 2012 1963-1991 Radiat Res Asia Cohort 
Current 
smoker 213 0 Mixed  2.0   1.5   2.6  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control Ex smoker 67 241 Males  1.3   1.0   1.8  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control Ex smoker 20 59 Females  1.6   0.80   3.4  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control 
Current 
smoker 48 136 Females  2.0   1.0   3.9  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control Ex smoker 358 1054 Males  2.1   1.7   2.6  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control 
Current 
smoker 591 1174 Males  3.2   2.6   3.9  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control 
Current 
smoker 184 293 Males  3.2   2.4   4.1  
Harris RE, 
1991 1991 1969-1991 Cancer Americas 
Case 
Control 
Ever 
smoker 26 35 Females  3.9   1.5   6.8  
Hartge P, 1987 1987 1977-1978 
J Natl Cancer 
Inst Americas 
Case 
Control Ex smoker 2324 3581 Mixed  1.7   1.5   2.0  
Hartge P, 1987 1987 1977-1978 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 2324 3581 Mixed  2.3   2.0   2.5  
Hartge P, 1987 1987 1977-1978 
J Natl Cancer 
Inst Americas 
Case 
Control 
Current 
smoker 2324 3581 Mixed  2.9   2.6   3.3  
Hosseini SY, 
2010 2010 2004-2008 Urol oncol Asia 
Case 
Control Ex smoker 3 6 Mixed  5.4   3.1   7.4  
Hosseini SY, 
2010 2010 2004-2008 Urol oncol Asia 
Case 
Control 
Ever 
smoker 42 17 Mixed  5.5   3.1   7.7  
Iscovich J, 
1987 1987 1983-1985 Int J Cancer Europe 
Case 
Control 
Ever 
smoker 91 144 Mixed  4.3   1.9   10.3  
Iscovich J, 
1987 1987 1983-1985 Int J Cancer Europe 
Case 
Control 
Current 
smoker 54 52 Mixed  7.2   3.0   20.1  
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort Ex smoker 277 0 Males  1.8   1.4   2.2  
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort 
Current 
smoker 638 0 Males  2.0   1.7   2.5  
Jensen OM, 
1987 1987 1979-1981 
J Epidemiol 
Community 
Health Europe 
Case 
Control 
Ever 
smoker 115 210 Mixed  2.9   1.8   4.8  
Karagas MR, 
2005 2005 1994-1997 Cancer Lett Americas 
Case 
Control 
Ever 
smoker 230 270 Males  1.4   0.90   2.1  
Karagas MR, 
2005 2005 1994-1997 Cancer Lett Americas 
Case 
Control 
Ever 
smoker 54 110 Females  1.9   1.1   3.3  
Kellen E, 2006 2006 1999-2004 Int J Cancer Europe 
Case 
Control Ex smoker 112 182 Mixed  2.2   1.4   3.6  
Kellen E, 2006 2006 1999-2004 Int J Cancer Europe 
Case 
Control 
Current 
smoker 55 44 Mixed  6.0   3.3   11.0  
Kunze E, 1991 1991 1977-1985 Cancer Europe 
Case 
Control Ex smoker 531 531 Males  1.8   1.0   3.2  
Kunze E, 1991 1991 1977-1985 Cancer Europe 
Case 
Control 
Current 
smoker 531 531 Males  3.5   2.0   6.4  
Lafuente A, 
1996 1996 1993-1994 Br J Cancer Africa Cohort 
Ever 
smoker 33 24 Mixed  1.3   0.59   2.8  
Lin J, 2006 2006 1999-2006 Cancer Americas 
Case 
Control 
Ever 
smoker 713 658 Mixed  2.3   1.8   2.9  
Liu Y, 2012 2012 2007-2011 Oncol reports Asia 
Case 
Control 
Ever 
smoker 214 609 Mixed  2.5   1.9   3.2  
Lopez-Abente 
G, 1991 1991 1985-1986 
Am J 
Epidemiol Europe 
Case 
Control Ex smoker 90 196 Mixed  2.7   1.6   4.5  
Lopez-Abente 
G, 1991 1991 1985-1986 
Am J 
Epidemiol Europe 
Case 
Control 
Ever 
smoker 396 618 Mixed  3.8   2.4   6.0  
Lopez-Abente 
G, 1991 1991 1985-1986 
Am J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 309 426 Mixed  4.4   2.8   7.0  
Lopez-Abente 
G, 2001 2001 1985-86 
J Epidemiol 
Community 
Health Europe 
Case 
Control 
Ever 
smoker 30 57 Mixed  7.3   2.1   26.1  
Malila N, 2006 2006 1984-1988 
Eur J Cancer 
Prev Europe 
Case 
Control 
Ever 
smoker 414 234 Mixed  1.8   1.6   2.0  
Miller CT, 
1978 1978 1977 J Chron Dis Americas 
Case 
Control 
Ever 
smoker 136 0 Males  1.6   0.96   2.7  
MILLS PK, 1991 1976-1982 Am J Americas Cohort Ex smoker 19 0 Mixed  2.4   1.3   4.7  
1991 Epidemiol 
MILLS PK, 
1991 1991 1976-1982 
Am J 
Epidemiol Americas Cohort 
Current 
smoker 4 0 Mixed  5.7   1.7   18.6  
Momas JP, 
1994 1994 1987-1989 
Eur J 
Epidemiol Europe 
Case 
Control 
Ever 
smoker 159 399 Mixed  5.3   2.9   9.6  
Mommsen S, 
1983 1983 1977-1980 
Eur J Cancer 
Clin Oncol Europe 
Case 
Control 
Ever 
smoker 22 30 Females  1.9   0.90   3.9  
Najem GR, 
1982 1982 1978 In J Epidemiol Americas 
Case 
Control 
Ever 
smoker 36 45 Mixed  2.0   1.1   3.7  
Nomura A, 
1989 1989 1977-1986 
Am J 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 31 49 Females  1.6   0.80   3.0  
Nomura A, 
1989 1989 1977-1986 
Am J 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 177 265 Males  4.8   2.7   8.2  
Nordlund LA, 
1997 1997 1964-1989 Int J cancer Europe Cohort 
Current 
smoker 102 0 Females  2.3   1.4   3.8  
Nordlund LA, 
1997 1997 1964-1989 Int J cancer Europe Cohort Ex smoker 102 0 Females  2.5   1.1   5.9  
Pelucchi C, 
2002 2002 1985-1992 Prev Med Europe 
Case 
Control Ex smoker 5 18 Females  1.1   0.36   3.6  
Pelucchi C, 
2002 2002 1985-1992 Prev Med Europe 
Case 
Control 
Ever 
smoker 47 73 Females  2.4   1.4   4.2  
Pelucchi C, 
2002 2002 1985-1992 Prev Med Europe 
Case 
Control 
Current 
smoker 42 55 Females  2.9   1.6   5.1  
Piper JM, 1986 1986 1975-1980 
Am J 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 134 24 Females  2.4   1.5   4.0  
Pitard A, 2001 2001 2001 CCC Europe 
Case 
Control 
Ever 
smoker 1420 2895 Mixed  3.5   2.9   4.2  
Pohlabeln H, 
1999 1999 1989-1992 
Eur J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 91 39 Mixed  5.2   2.7   9.7  
Pommer W, 
1999 1999 1990-1994 
Nephrol Dial 
Transplant Europe 
Case 
Control Ex smoker 180 209 Mixed  1.6   1.1   2.2  
Pommer W, 
1999 1999 1990-1994 
Nephrol Dial 
Transplant Europe 
Case 
Control 
Current 
smoker 253 144 Mixed  3.2   2.3   4.5  
Puente D, 2006 1976-1996 CCC Europe Case Ex smoker 2669 5381 Males  2.2   2.0   2.4  
2006 Control 
Puente D, 
2006 2006 1976-1996 CCC Europe 
Case 
Control Ex smoker 309 739 Females  2.2   1.9   2.6  
Puente D, 
2006 2006 1976-1996 CCC Europe 
Case 
Control 
Current 
smoker 611 973 Females  3.6   3.1   4.1  
Puente D, 
2006 2006 1976-1996 CCC Europe 
Case 
Control 
Current 
smoker 3020 3759 Males  3.9   3.5   4.3  
Quirk JT, 2004 2004 1982-1998 Tob Ind Dis Americas 
Case 
Control Ex smoker 274 927 Mixed  2.1   1.6   2.7  
Quirk JT, 2004 2004 1982-1998 Tob Ind Dis Americas 
Case 
Control 
Ever 
smoker 396 1198 Mixed  2.4   1.9   3.0  
Quirk JT, 2004 2004 1982-1998 Tob Ind Dis Americas 
Case 
Control 
Current 
smoker 122 271 Mixed  3.4   2.5   4.6  
Rebelakos A, 
1985 1985 1980-1982 
J Natl Cancer 
Institute Europe 
Case 
Control Ex smoker 300 300 Mixed  2.0   1.2   3.3  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control Ex smoker 6 6 Females  1.8   0.50   7.2  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control 
Ever 
smoker 27 12 Females  3.3   1.3   8.0  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control Ex smoker 453 464 Males  3.8   2.8   5.3  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control 
Ever 
smoker 950 782 Males  5.1   3.7   7.0  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control 
Current 
smoker 21 6 Females  5.1   1.6   16.4  
Samanic C, 
2006 2006 1998-2000 
Cancer 
Epidemiol 
Biomarkers 
prev Europe 
Case 
Control 
Current 
smoker 492 314 Males  7.4   5.3   10.4  
Schifflers E, 
1987 1987 1984-1985 Int J Cancer Europe 
Case 
Control 
Ever 
smoker 74 74 Mixed  5.3   1.6   18.1  
Shakhssalim, 
2010 2010 2005-2006 
Asian Pac J 
Cancer Prev Asia 
Case 
Control 
Ever 
smoker 399 627 Mixed  2.0   1.5   2.6  
Shankar A, 
2007 2007 1993-1998 Eur J Cancer Asia Cohort Ex smoker 146 0 Mixed  2.7   1.4   5.2  
Siemiatycki J, 
1994 1994 1979-1984 Epidemiology Americas 
Case 
Control 
Ever 
smoker 844 1371 Mixed  15.8   8.7   29.1  
Siemtiatycki J, 
1995 1995 1979-1985 In J Epidemiol Americas 
Case 
Control 
Ever 
smoker 441 0 Mixed  2.4   1.6   3.6  
Slattery ML, 
1988 1988 1977-1983 Cancer Americas 
Case 
Control 
Current 
smoker 91 111 Males  3.7   2.6   5.3  
Steineck G, 
1988 1988 1967-1968 
Acta 
Oncologica Europe Cohort 
Ever 
smoker 54 0 Mixed  1.9   0.80   4.7  
Terry  PD, 
2006 2006 2005 Int j cancer Americas 
Case 
Control Ex smoker 138 110 Mixed  3.2   1.9   5.4  
Terry  PD, 
2006 2006 2005 Int j cancer Americas 
Case 
Control 
Current 
smoker 60 26 Mixed  6.3   3.3   12.0  
Tulinus H, 
1997 1997 1967-1991 
Cancer 
Epidemiol 
Biomarkers 
prev Europe Cohort Ex smoker 167 0 Males  2.3   1.4   3.9  
Vineis P, 1988 1988 1977-1983 Cancer res Europe 
Case 
Control Ex smoker 22 62 Mixed  2.1   1.1   4.0  
Vineis P, 1988 1988 1977-1983 Cancer res Europe 
Case 
Control Ex smoker 30 45 Mixed  2.5   1.3   5.0  
Vineis P, 1988 1988 1977-1983 Cancer res Europe 
Case 
Control 
Current 
smoker 151 127 Mixed  5.5   3.2   9.5  
Vineis P, 1988 1988 1977-1983 Cancer res Europe 
Case 
Control 
Current 
smoker 65 47 Mixed  6.2   3.3   11.7  
Vizcaino AP, 1994 1963-1977 CCC Africa Case Ex smoker 2 60 Mixed  0.30   0.10   1.4  
1994 Control 
Vizcaino AP, 
1994 1994 1963-1977 CCC Africa 
Case 
Control 
Current 
smoker 142 1117 Mixed  1.1   0.80   1.4  
Wakai K, 1993 1993 1976-1978 
Jpn J Cancer 
Res Asia Cohort 
Ever 
smoker 175 0 Males  0.88   0.45   1.7  
Yun YH, 2005 2005 1996-2000 
Cancer Detect 
Prev Asia Cohort Ex smoker 52 0 Mixed  0.96   0.65   1.4  
Yun YH, 2005 2005 1996-2000 
Cancer Detect 
Prev Asia Cohort 
Current 
smoker 137 0 Mixed  2.2   1.5   3.4  
Zarzour AH, 
2008 2008 2005 BMC cancer Africa 
Case 
Control 
Ever 
smoker 130 260 Mixed  5.3   3.2   8.7  
Zeegers MPA, 
2002 2002 1986-1992 CCC Europe Cohort Ex smoker 263 0 Mixed  2.1   1.5   3.0  
Zeegers MPA, 
2002 2002 1986-1992 CCC Europe Cohort 
Current 
smoker 282 0 Mixed  3.3   2.4   4.0  
Zhang ZF, 
1994 1994 1972-1980 
Cancer 
Epidemiol 
Biomarkers 
prev Americas Cohort 
Ever 
smoker 77 0 Mixed  1.7   0.70   4.0  
Zheng YL, 
2012 2012 2006-2010 
Cancer 
Epidemiol 
Biomarkers 
prev Africa 
Case 
Control Ex smoker 114 280 Males  1.2   0.90   1.7  
Zheng YL, 
2012 2012 2006-2010 
Cancer 
Epidemiol 
Biomarkers 
prev Africa 
Case 
Control 
Current 
smoker 525 908 Males  2.1   1.7   2.6  
 
 
Supplementary table 1b All study data for Bladder Cancer Mortality 
 
Author Year  
Years of 
follow up Journal Region 
Study 
Design 
Risk 
group Cases Controls Gender 
Risk 
effect 
Lower 
CI 
Upper 
CI 
Fleshner N, 1999 1995-1995 Cancer Americas Cohort Ex smoker 51 0 Mixed 0.99 0.77 1.3 
1999 
Fleshner N, 
1999 1999 1995-1995 Cancer Americas Cohort 
Current 
smoker 108 0 Mixed 1.4 1.0 1.9 
Freedman ND, 
2011 2011 1995-1996 JAMA Europe Cohort Ex smoker 2483 0 Males 2.1 1.9 2.4 
Freedman ND, 
2011 2011 1995-1996 JAMA Americas Cohort 
Current 
smoker 206 0 Females 4.7 3.7 5.8 
Freedman ND, 
2011 2011 1995-1996 JAMA Americas Cohort 
Current 
smoker 809 0 Females 2.5 2.1 3.1 
Freedman ND, 
2011 2011 1995-1996 JAMA Americas Cohort Ex smoker 288 0 Males 3.9 3.5 4.4 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort 
Current 
smoker 105 0 Males 1.9 1.2 3.0 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort Ex smoker 50 0 Males 1.6 0.90 2.6 
Kurahashi N, 
2009 2009 1990-1993 Cancer Sci Asia Cohort Ex smoker 42 0 Mixed 1.3 0.78 2.1 
Kurahashi N, 
2009 2009 1990-1993 Cancer Sci Asia Cohort 
Current 
smoker 92 0 Mixed 1.5 0.92 2.3 
McCormack 
VA, 2010 2010 1991-1998 Int J Cancer Europe Cohort 
Ever 
smoker 349 0 Mixed 2.9 2.3 3.7 
Nilsson S, 
2001 2001 1960-1996 
J Epidemiol 
Community 
Health Europe Cohort Ex smoker 2 0 Females 1.0 0.24 4.2 
Nilsson S, 
2001 2001 1960-1996 
J Epidemiol 
Community 
Health Europe Cohort 
Current 
smoker 9 0 Females 1.4 0.67 2.9 
Nilsson S, 
2001 2001 1960-1996 
J Epidemiol 
Community 
Health Europe Cohort Ex smoker 29 0 Males 2.2 1.3 3.7 
Nilsson S, 
2001 2001 1960-1996 
J Epidemiol 
Community 
Health Europe Cohort 
Current 
smoker 25 0 Males 2.2 1.2 3.9 
Rink M, 2012 2012 1987-2007 Eur Urol Americas Cohort Ex smoker 956 0 Mixed 1.1 0.86 1.4 
Rink M, 2012 2012 1987-2007 Eur Urol Americas Cohort Current 593 0 Mixed 1.1 0.85 1.5 
smoker 
Sfakianos JP, 
2011 2011 1994-2008 BJU Int Americas Cohort 
Ever 
smoker 483 0 Mixed 1.1 0.79 1.6 
Wen CP, 2004 2004 1982-1992 Prev Med Asia Cohort 
Current 
smoker 15 0 Males 1.7 0.65 4.5 
 
 
Supplementary table 1c All study data for Renal Cell Cancer Incidence 
 
Author Year  
Years of 
follow up Journal Region 
Study 
Design 
Risk 
Group Cases Controls Gender 
Risk 
effect 
Lower 
CI 
Upper 
CI 
Brennan P, 
2008 2008 1999-2003 Br J Cancer Europe 
Case 
Control 
Current 
smoker 333 521 Mixed 0.87 0.71 1.1 
Brennan P, 
2008 2008 1999-2003 Br J Cancer Europe 
Case 
Control Ex smoker 251 353 Mixed 0.88 0.71 1.1 
Chiu BC, 
2001 2001 1986-1989 Ann Epidemiol Americas 
Case 
Control 
Ever 
smoker 53 259 Females 1.2 0.80 1.8 
Chiu BC, 
2001 2001 1986-1989 Ann Epidemiol Americas 
Case 
Control 
Current 
smoker 92 574 Females 1.4 0.90 2.3 
Chiu BC, 
2001 2001 1986-1989 Ann Epidemiol Americas 
Case 
Control 
Ever 
smoker 202 1068 Males 1.8 1.3 2.7 
Chiu BC, 
2001 2001 1986-1989 Ann Epidemiol Americas 
Case 
Control 
Current 
smoker 40 435 Males 2.1 1.3 3.2 
Engeland A, 
1996 1996 1964-1965 CCC Europe Cohort Ex smoker 1 0 Females 1.1 0.60 2.0 
Engeland A, 
1996 1996 1964-1965 CCC Europe Cohort Ex smoker 28 0 Males 1.3 0.80 2.4 
Flaherty KT, 
2005 2005 1976-2000 CCC Americas Cohort 
Current 
smoker 22 0 Females 0.90 0.60 1.5 
Flaherty KT, 
2005 2005 1976-2000 CCC Americas Cohort Ex smoker 68 0 Females 1.3 0.90 1.8 
Flaherty KT, 
2005 2005 1976-2000 CCC Americas Cohort Ex smoker 62 0 Males 1.4 0.90 2.2 
Flaherty KT, 
2005 2005 1976-2000 CCC Americas Cohort 
Current 
smoker 8 0 Males 1.3 0.60 2.9 
Goodman 
MT, 1986 1986 1977-1983 
Am J 
Epidemiol Americas 
Case 
Control 
Ever 
smoker 145 142 Mixed 1.1 0.67 1.8 
Hu J, 2005 2005 1994-1997 Eur J Cancer Americas 
Case 
Control 
Current 
smoker 113 558 Males 0.90 0.70 1.2 
Hu J, 2005 2005 1994-1997 Eur J Cancer Americas 
Case 
Control Ex smoker 386 1354 Males 1.2 1.0 1.5 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort 
Current 
smoker 324 0 Males 1.3 1.0 1.5 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort Ex smoker 194 0 Males 1.2 0.90 1.6 
Kreiger N, 
1991 1991 1986-86 CCC Americas 
Case 
Control 
Ever 
smoker 114 306 Females 1.9 1.3 2.6 
Kreiger N, 
1991 1991 1986-86 CCC Americas 
Case 
Control 
Ever 
smoker 245 449 Males 2.0 1.4 2.8 
Kreiger N, 
1991 1991 1986-86 CCC Americas 
Case 
Control 
Current 
smoker 67 158 Females 2.2 1.5 3.2 
Kreiger N, 
1991 1991 1986-86 CCC Americas 
Case 
Control 
Current 
smoker 102 174 Males 2.3 1.5 3.4 
La Vecchia C, 
1990 1990 1985-1990 Cancer Res Europe 
Case 
Control Ex smoker 32 96 Mixed 1.7 1.0 3.1 
McCredie M, 
1992 1992 1989-1990 Eur J Cancer Oceania 
Case 
Control Ex smoker 110 0 Mixed 1.4 1.0 2.0 
McCredie M, 
1992 1992 1989-1990 Eur J Cancer Oceania 
Case 
Control 
Current 
smoker 83 0 Mixed 2.2 1.6 3.0 
McLaughlin 
JK, 1984 1984 1974-1979 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 148 171 Males 1.7 1.1 2.6 
McLaughlin 
JK, 1984 1984 1974-1979 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 89 92 Females 1.9 1.3 3.1 
McLaughlin 
JK, 1990 1990 1954-1980 
Public Healh 
Rep Americas Cohort Ex smoker 111 0 Mixed 1.1 0.85 1.4 
McLaughlin 
JK, 1990 1990 1954-1980 
Public Healh 
Rep Americas Cohort 
Current 
smoker 284 0 Mixed 1.5 1.2 1.8 
McLaughlin 1992 1987-1989 Int J Cancer Asia Case Ever 67 57 Mixed 2.3 1.1 4.9 
JK, 1992 Control smoker 
McLaughlin 
JK, 1995 1995 1989-1991 Int J cancer Americas 
Case 
Control Ex smoker 545 762 Mixed 1.2 1.0 1.4 
McLaughlin 
JK, 1995 1995 1989-1991 Int J cancer Americas 
Case 
Control 
Ever 
smoker 1083 1354 Mixed 1.3 1.1 1.5 
McLaughlin 
JK, 1995 1995 1989-1991 Int J cancer Americas 
Case 
Control 
Current 
smoker 538 592 Mixed 1.4 1.2 1.7 
Mellemgaard 
A, 1994 1994 1989-1991 CCC Europe 
Case 
Control Ex smoker 82 89 Males 1.0 0.50 2.0 
Mellemgaard 
A, 1994 1994 1989-1991 CCC Europe 
Case 
Control 
Current 
smoker 48 52 Females 1.1 0.60 2.0 
Mellemgaard 
A, 1994 1994 1989-1991 CCC Europe 
Case 
Control 
Current 
smoker 96 92 Males 1.1 0.60 2.1 
Mellemgaard 
A, 1994 1994 1989-1991 CCC Europe 
Case 
Control Ex smoker 34 34 Females 1.2 0.70 2.3 
Muscat JE, 
1995 1995 1973-1991 Cancer Americas 
Case 
Control Ex smoker 200 226 Males 0.90 0.70 1.5 
Muscat JE, 
1995 1995 1973-1991 Cancer Americas 
Case 
Control 
Current 
smoker 70 135 Females 1.0 0.70 1.6 
Muscat JE, 
1995 1995 1973-1991 Cancer Americas 
Case 
Control Ex smoker 50 50 Females 1.1 0.70 1.7 
Muscat JE, 
1995 1995 1973-1991 Cancer Americas 
Case 
Control 
Current 
smoker 174 128 Males 1.4 1.0 2.0 
Nordlund LA, 
1997 1997 1964-1989 Int J cancer Europe Cohort 
Current 
smoker 94 0 Females 1.1 0.59 2.0 
Nordlund LA, 
1997 1997 1964-1989 Int J cancer Europe Cohort Ex smoker 94 0 Females 1.9 0.75 4.7 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control Ex smoker 426 798 Mixed 0.90 0.80 1.1 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control Ex smoker 73 798 Mixed 0.90 0.60 1.2 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control 
Current 
smoker 17 785 Mixed 0.70 0.40 1.3 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas Case Current 430 785 Mixed 1.1 0.70 1.6 
Control smoker 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control Ex smoker 117 798 Mixed 1.2 0.90 1.6 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control Ex smoker 19 798 Mixed 0.60 0.20 1.8 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control 
Current 
smoker 104 785 Mixed 1.2 0.70 2.1 
Purdue, 2013 2013 2002-2007 Int J Cancer Americas 
Case 
Control 
Current 
smoker 69 785 Mixed 1.2 0.70 2.1 
Schlehofer B, 
1995 1995 1989-1991 
Int J 
Epidemiol Europe 
Case 
Control Ex smoker 14 14 Females 0.99 0.43 1.4 
Schlehofer B, 
1995 1995 1989-1991 
Int J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 18 21 Females 0.83 0.39 1.8 
Schlehofer B, 
1995 1995 1989-1991 
Int J 
Epidemiol Europe 
Case 
Control Ex smoker 70 80 Males 1.1 0.63 1.9 
Schlehofer B, 
1995 1995 1989-1991 
Int J 
Epidemiol Europe 
Case 
Control 
Current 
smoker 81 70 Males 1.4 0.82 2.5 
Setiawan VW, 
2007 2007 1993-1996 Am J Epi Americas Cohort Ex smoker 42 0 Females 1.3 0.90 2.0 
Setiawan VW, 
2007 2007 1993-1996 Am J Epi Americas Cohort Ex smoker 119 0 Males 1.5 1.1 2.1 
Setiawan VW, 
2007 2007 1993-1996 Am J Epi Americas Cohort 
Current 
smoker 22 0 Females 1.7 1.0 2.8 
Setiawan VW, 
2007 2007 1993-1996 Am J Epi Americas Cohort 
Current 
smoker 53 0 Males 2.3 1.6 3.4 
Sharpe CR, 
1989 1989 1987 CMAJ Americas 
Case 
Control 
Current 
smoker 26 42 Mixed 0.53 0.30 0.95 
Sharpe CR, 
1989 1989 1987 CMAJ Americas 
Case 
Control Ex smoker 104 106 Mixed 0.90 0.57 1.5 
Siemtiatycki 
J, 1995 1995 1979-1985 In J Epidemiol Americas 
Case 
Control 
Ever 
smoker 143 0 Mixed 1.0 0.70 1.6 
Talamini R, 
1990 1990 1986-1989 CCC Europe 
Case 
Control Ex smoker 55 161 Mixed 1.4 0.83 2.2 
Wang G, 2012 2007-2009 Cancer Asia Case Ever 74 85 Mixed 0.95 0.63 1.4 
2012 Epidemiol Control smoker 
Yu MC, 1986 1986 1975-1979 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 33 32 Females 1.1 0.50 2.4 
Yu MC, 1986 1986 1975-1979 
J Natl Cancer 
Inst Americas 
Case 
Control 
Ever 
smoker 88 75 Males 2.1 1.1 4.4 
Yuan JM, 
1998 1998 1986-1994 
Cancer 
Epidemiol 
Biomarkers 
prev Americas 
Case 
Control Ex smoker 463 450 Mixed 1.2 1.0 1.5 
Yuan JM, 
1998 1998 1986-1994 
Cancer 
Epidemiol 
Biomarkers 
prev Americas 
Case 
Control 
Ever 
smoker 800 713 Mixed 1.4 1.1 1.6 
Yuan JM, 
1998 1998 1986-1994 
Cancer 
Epidemiol 
Biomarkers 
prev Americas 
Case 
Control 
Current 
smoker 337 262 Mixed 1.5 1.2 1.9 
Yun YH, 2005 2005 1996-2000 
Cancer Detect 
Prev Asia Cohort 
Current 
smoker 106 0 Mixed 0.94 0.66 1.3 
Yun YH, 2005 2005 1996-2000 
Cancer Detect 
Prev Asia Cohort Ex smoker 42 0 Mixed 1.3 0.80 2.1 
 
 
Supplementary table 1d All study data for Renal Cell Cancer Mortality 
 
Author Year  
Years of 
follow up Journal Region 
Study 
Design 
Risk 
group Cases Controls Gender 
Risk 
effect 
Lower 
CI 
Upper 
CI 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort 
Current 
smoker 90 0 Males 1.0 0.70 1.5 
Jee SH, 2004 2004 1992-1995 CCC Asia Cohort Ex smoker 56 0 Males 1.2 0.80 1.9 
McCormack 
VA, 2010 2010 1991-1998 Int J Cancer Europe Cohort 
Ever 
smoker 117 0 Mixed 1.3 0.90 1.8 
Parker A, 
2008 2008 1970-2002 Int J Urol Americas Cohort Ex smoker 2242 0 Mixed 0.93 0.79 1.1 
Parker A, 
2008 2008 1970-2002 Int J Urol Americas Cohort 
Current 
smoker 2242 0 Mixed 1.3 1.1 1.6 
Sweeney C, 
2000 2000 1995-1997 Epidemiology Americas Cohort 
Current 
smoker 62 0 Mixed 1.7 1.2 2.5 
Sweeney C, 
2000 2000 1995-1997 Epidemiology Americas Cohort Ex smoker 185 0 Mixed 1.2 0.80 1.7 
Wen CP, 
2004 2004 1982-1992 Prev Med Asia Cohort 
Current 
smoker 9 0 Males 1.6 0.59 4.6 
 
 
 
 
 
Supplementary Table 2 Pooled relative risks (RRs) and 95% confidence intervals (CIs) for incidence from Bladder Cancer in 
smokers of non-cigarette tobacco. 
Non-cigarette 
tobacco 
product 
Incidence 
No. of  
studies 
Pooled RR  
(95% CI) 
I2 (p for 
heterogeneity) 
Cigars 4 1.62 
(1.18-2.22) 
39.4% (0.2) 
Pipes 4 1.49 
(1.18-1.88) 
0.0% (0.6) 
Snuff 2 0.89 
(0.56-1.42) 
23.7% (0.6) 
Cigarillos 1 1.00 
(0.41-2.50) 
-- 
Chewing 2 1.04 
(0.75-1.45) 
0.0% (0.9) 
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European Urology 
Editorial Office 
 
 
 
Dear Editorial office, 
Re: The role of tobacco smoke in bladder and kidney carcinogenesis: A 
comparison of exposures and meta-analysis of incidence and mortality 
risks 
Thank you for taking the time to review our revised manuscript.  We believe we 
have overcome the remaining key concerns raised by the editorial team and have 
addressed each reviewer comment in detail (please see below). We thank you for 
your time and consideration. 
 
Yours sincerely, 
Marcus Cumberbatch 
 
 
 
Comments to Author: 
 
Reviewer #3:  I have only three small grammatical 
comments at this point: 
 
On line 379, please change to "non muscle-invasive 
(NMIBC) versus muscle-invasive bladder cancer (MIBC).  
Line 386, change "our" to "out" 
Would consider flip flopping the last two sentences 
in the conclusions as the last sentence is not a 
strong ending (lines 397 to 401). 
 
This has been done. 
 
Reviewer #5: EUROPEAN UROLOGY STATISTICAL REVIEW 
 
Minor comments 
1)    Please follow the European Urology guidelines 
for presentation of statistics: 
http://www.europeanurology.com/article/S0302-
2838(14)00598-3/pdf/guidelines-for-reporting-of-
*Revision notes
statistics-in-european-urology. In particular, 
precision is often misreported. P values are often 
given categorically (e.g. p<0.05) or to inappropriate 
precision (e.g. p=0.59). Estimates are reported to 
extremely different levels of precision in 
supplementary table 1a. 
2)    Report p values for the main hypotheses, which 
are whether tobacco influences risk. 
3)    Is opium tobacco? 
4)    Line 233: the ".0" in the p value of 1.0 is 
somewhat redundant. 
5)    Line 235 and 247: you are accepting the null 
hypothesis (guideline 3.1) 
 
This has been done. 
  
Major comments 
  
1)    Do not report I2. I am aware that this is 
commonly reported, but is, in my view, invalid. I2 
should either by 0 (there isn't heterogeneity) or 1 
(there is heterogeneity); the only reason it is not 1 
or 0 is inadequate sample size.  The I2 statistics 
are all very large here because sample sizes are 
large. Instead of this statistic, report a p value 
for heterogeneity. However, and this is the critical 
point, don't just report "heterogeneity / no 
heterogeneity" and be done with it. You have to 
investigate sources of heterogeneity and come to some 
scientific conclusions about what it means. 
 
We disagree on this point. The I
2
 heterogeneity 
statistic does not depend only on the number of 
studies included in the meta-analysis. It is in fact 
true that with a small number of studies 
statistically significant heterogeneity would be 
evident only when the heterogeneity is high. With a 
high number of studies it is more likely to find a 
significant heterogeneity, but this is not a rule, 
and the I
2
 could be 0 as well as 10 or 50%. We would 
prefer to keep them, as in other meta-analyses 
published by European Urology (please see µA 
Systematic Review and Meta-analysis of Tobacco Use 
and Prostate Cancer Mortality and Incidence in 
Prospective Cohort Studies¶ by Islami et al: URL: 
http://www.ncbi.nlm.nih.gov/pubmed/25242554). This 
gives to the reader a useful measure to interpret the 
findings. 
We have tried to investigate, and discuss, potential 
sources of heterogeneity by undertaking stratified 
analyses by sex and geographical area of the studies, 
two of the most consistently reported data across 
studies. Since this is a meta-analysis of published 
data, we were however unable to identify other 
potential modifier effects since not consistently 
reported across studies. However, when possible we 
used the maximally adjusted estimates for the meta-
analysis in order to reduce the risk of possible 
unmeasured confounding (lines 161-164). 
 
2)    The authors conduct subgroup analyses rather 
than interaction analyses (see guideline 3.5). We are 
not interested in the estimate of the effects of 
smoking in men and then separately in women; we want 
to know whether the effects of smoking differ between 
men and women. Similarly, we don't want to know the 
risk estimates separately for cigars, snuff etc. etc. 
but whether these are higher or lower than for 
cigarettes. 
 
We agree with the reviewer. Since we are not dealing 
with original but with published data, in meta-
analysis settings the possible interaction effect can 
be tested by comparing pooled risk estimates across 
strata of a possible modifier effect. In the current 
version of the manuscript we provided in the text the 
p-values for the difference of pooled RR across sex, 
geographical area and type of smoking (non-cigarette 
vs sigarette tobacco). 
 
